OshudEsmolol Hydrochloride
Anti adrenergic agent (Beta blockers)
Brands & Prices (1)
📋 Indications & Uses Dosage & Administration⚠️ Contraindications⚡ Side Effects & Adverse Reactions🛡️ Warnings & Precautions🔬 Pharmacology & Mechanism
Brand Formulations & Prices
1 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAdrebloc is a beta adrenergic blocker indicated for the short-term
treatment of:
Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia.
Control of perioperative tachycardia and hypertension.
Dosage & AdministrationAdminister intravenously. Titrate using ventricular rate or blood pressure at ≥4 minute intervals. Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia-
Optional loading dose: 500 mcg per kg infused over one minute
Then 50 mcg per kg per minute for the next 4 minutes
Adjust dose as needed to a maximum of 200 mcg per kg per minute
Additional loading doses may be administered
Perioperative tachycardia and hypertension-
Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control).
Than 50 mcg per kg per minute for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per minute.
Severe sinus bradycardia
Heart block greater than first degree
Sick sinus syndrome
Decompensated heart failure
Cardiogenic shock
Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to Esmolol hydrochloride
Pulmonary hypertension
Known hypersensitivity to esmolol
Most common adverse reactions (incidence> 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.
Risk of hypotension, bradycardia, and cardiac failure: Reduce or discontinue use
Risk of exacerbating reactive airway disease
Diabetes mellitus: Increases the effect of hypoglycemic agents and masks hypoglycemic tachycardia
Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma
Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease
Esmolol Hydrochloride is a beta-1 selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol Hydrochloride inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature.